A new protein targeted treatment for B-cell lymphoma
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
Using synthetic antibodies to treat diffuse midline gliomas
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Using existing drugs in a new way to treat high-risk acute lymphoblastic leukaemia
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.
Paediatric Hepatic International Tumour Trial
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Developing less toxic therapies for children with acute lymphoblastic leukaemia
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Accelerating drugs into clinical trials for patients with Ewing sarcoma
Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.
Improving bone marrow transplant for patients with high-risk leukaemia
Investigating a new method to improve the success of bone marrow transplants, using a different type of blood cells.